Table 2 Radiopharmaceutical specifications. Data are displayed in means (standard error of the mean)
From: The effects of molar activity on [18F]FDOPA uptake in patients with neuroendocrine tumors
Group 1 (no evidence of disease) | Group 2 (1–2 lesions) | Group 3 (3–10 lesions) | |
|---|---|---|---|
Activity administered (MBq) | [18F]FDOPA-L: 192 (2.3) | [18F]FDOPA-L: 205 (3.3) | [18F]FDOPA-L: 180 (7.9) |
[18F]FDOPA-H: 204 (4.0) | [18F]FDOPA-H: 192 (11.2) | [18F]FDOPA-H: 205 (2.1) | |
p value (t test) | 0.05 | 0.10 | < 0.001* |
Injected mass (µg) | [18F]FDOPA-L: 5204 (356) | [18F]FDOPA-L: 4614 (1028) | [18F]FDOPA-L: 5167 (694) |
[18F]FDOPA-H: 515 (50) | [18F]FDOPA-H: 1205 (371) | [18F]FDOPA-H: 885 (283) | |
p value (t test) | < 0.001* | 0.005* | < 0.001* |